Fig. 1: Expression of IBTKα, LPL, CD38 and ZAP70 in CLL patients | Cell Death & Disease

Fig. 1: Expression of IBTKα, LPL, CD38 and ZAP70 in CLL patients

From: The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Fig. 1

. a–d B-cells were isolated from healthy donors (HD), and CLL patients of Binet A, B, C and In-Therapy groups. Total RNA was analysed by RT-qPCR for the expression of IBTKα a, CD38 b, ZAP70 c, and LPL d. β-ACTIN expression was measured for normalisation. Statistical analysis was performed using Mann–Whitney test (GraphPad Prism 6). e Protein extracts from healthy donors (HD) and CLL patients of Binet A (CLL9, 13, 16, 21, 29, 33), Binet B (CLL3, 6, 20, 37) and Binet C (CLL30, 46) stages. Proteins were separated by 4-12% NuPAGE Novex Gels (ThermoFisher Scientific) and analysed by Western blotting with antibodies against IBtkα (ThermoFisher Scientific #PA5-24224) and β-actin (Cell Signalling #3700S). f IBTKα gene expression in CLL11 patient before and after first line therapy with Rituximab and Bendamustine. Total RNA was analysed by RT-qPCR. Mean values (n = 3) ± SE are shown. Statistical analysis was performed using Unpaired t-test with Welch’s correction (GraphPad Prism 6). g IBtkα protein content in CLL11 patient before and after first line therapy with Rituximab and Bendamustine. Protein extracts were analysed by Western blotting with antibodies against IBtkα (ThermoFisher Scientific #PA5-24224) and β-actin (Cell Signalling #3700 S). n.s. indicates non-specific bands

Back to article page